Lifeboat Foundation

Billionaire investor Jim Mellon has joined the push to solve age-related diseases and bring rejuvenation biotechnology to the world.

Billionaire biotechnology investor Jim Mellon has unveiled an investment in an ambitious new venture which seeks to tackle ageing and age-related diseases.

Insilico Medicine is a big data analytics company which says its mission is to ‘extend healthy longevity’.

Continue reading “Billionaire Jim Mellon invests in anti-ageing research firm” »

https://www.youtube.com/watch?v=kEGccyXSQAU

New one from Liz.

Full Video ► https://goo.gl/tHvTF5
BioViva ► http://bioviva-science.com

Continue reading “Liz Parrish — Human of the Future” »

The ruling class tell us universal healthcare is ‘unfeasible’ while they pour millions into immortality drugs and seek godhood itself.

Interest in rejuvenation biotechnology is growing rapidly and attracting investors.

- Jim Mellon has made an investment in Insilico Medicine to enable the company to validate the many molecules discovered using deep learning and launch multi-modal biomarkers of human aging

Monday, April 10, 2017, Baltimore, MD — Insilico Medicine, Inc, a big data analytics company applying deep learning techniques to drug discovery, biomarker development, and aging research today announced that it has closed an investment from the billionaire biotechnology investor Jim Mellon. Proceeds will be used to perform pre-clinical validation of multiple lead molecules developed using Insilico Medicine’s drug discovery pipelines and to advance research in deep learned biomarkers of aging and disease.

Continue reading “Billionaire investor to accelerate research in artificial intelligence in healthcare” »

Dismantling the idea that older generations should ‘step down’ for younger ones.

Humans are really pros at sugarcoating. If you say old people should step down for the sake of new generations, it sounds so noble and rightful, doesn’t it? What it actually means, though, is ‘We value old people less than new ones,’ and this doesn’t sound very noble or rightful. This is plain and brutal survival of the species.

Continue reading “Old generations should step down in favour of the new ones” »

Everolimus heading for human clinical trials later this year to treat immune system decline.

The biotechnology company PureTech are moving towards human clinical trials with a new therapy that may slow down the aging process and combat age-related disease. The company has licensed two new drug candidates, derivatives of the drug Rapamycin, from pharmaceutical giant Novartis.

PureTech have recently announced a joint venture with Novartis called resTORbio and are moving to clinical trials of the new drugs later this year. The aim of the first test phase is to see if the new drug can rejuvenate the immune system of aged people a key reason why we lose the ability to resist diseases as we grow older.

Continue reading “New drug aimed at slowing aging heads to the clinic” »

For people in that area, and it may be worth while to try reaching out to them for funding for anti aging stuff.

Why is RAND opening a Bay Area office?

The San Francisco Bay Area is really at the center of technology and transformation. That’s also been a focus at RAND since our very first report, Preliminary Design of an Experimental World-Circling Spaceship, in 1946, which foretold the creation of satellites more than a decade before Sputnik.

Continue reading “Innovation in the Bay Area: Q&A with Nidhi Kalra” »

I enjoy meeting authors to discuss their ideas and I met Jim Mellon at the Master Investor show and purchased his book called Fast Forward: The.

The first step in producing an artificial thymus which has potential for cancer age related immune decline.

UCLA researchers have created a new system to produce human T cells, the white blood cells that fight against disease-causing intruders in the body. The system could be utilized to engineer T cells to find and attack cancer cells, which means it could be an important step toward generating a readily available supply of T cells for treating many different types of cancer.

The preclinical study, published in the journal Nature Methods, was led by senior authors Dr. Gay Crooks, a professor of pathology and laboratory medicine and of pediatrics and co-director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA, and Amelie Montel-Hagen, an associate project scientist in Crooks’ lab.

Continue reading “Artificial thymus can produce cancer-fighting T cells from blood stem cells” »